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Abstract 20 
Purpose  While animal and in vitro data demonstrate vasodilatory effects of egg-white derived peptides, human 21 
studies are lacking.  We investigated for the first time the effects of an egg ovalbumin-derived protein hydrolysate 22 
on blood pressure (BP) and cardiovascular risk.   23 
Methods  A double-blind, placebo-controlled randomized crossover trial was implemented in 75 adults aged 50-24 
70yrs with systolic BP (130– ≤150 mmHg).  Participants were randomized to an egg ovalbumin derived-protein 25 
hydrolysate (3g/d) or placebo (3g/d).  Participants completed two 6-week periods separated by a 3-week washout.   26 
Results  Data from 65 participants with a mean systolic BP (135.1±11 mmHg) were included.  Mean office and 27 
central BP and arterial stiffness (assessed by carotid-femoral pulse wave velocity (cfPWV) or pulse wave analysis 28 
(PWA)) did not change over time and no significant differences were observed between the egg-protein 29 
hydrolysate and placebo groups (P> 0.05).  Similarly, no significant effects of this egg ovalbumin-derived protein 30 
hydrolysate on blood lipid and glucose concentrations (P> 0.05) were observed. 31 
Conclusion  This is the first dietary intervention to investigate the effects of egg ovalbumin-derived protein 32 
hydrolysates on cardiovascular risk in humans. Despite promising findings from animal and in vitro studies, this 33 
RCT does not support the hypothesis that consumption of an egg ovalbumin-derived-protein hydrolysate for 6-34 
weeks in adults with a high-normal BP results in a reduction in BP or the modification of cardiovascular risk. 35 
 36 
Keywords: Bioactive peptides, blood pressure, cardiovascular risk, egg white, ovalbumin. 37 
  38 
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Introduction 39 
Cardiovascular disease (CVD) is the leading global cause of mortality, accounting for ~31% of deaths [1].  40 
Hypertension is one of the major controllable risk factors associated with CVD [2].  Dietary factors play a 41 
significant role in the prevention of hypertension and the maintenance of normal blood pressure (BP) [3, 4]; 42 
therefore, efforts are being placed on the development of foods with anti-hypertensive activity. 43 
Many dietary proteins contain peptide sequences (between 2-50 amino acid residues) encrypted within 44 
their primary structure that are capable of modulating specific physiological functions once released by digestive 45 
enzymes during gastrointestinal transit or by fermentation or ripening during food processing [5].  There is 46 
increasing evidence that these bioactive peptides naturally present in dairy, cereals and fish may reduce vascular 47 
risk most notably by reducing BP [6 -8].  The formulation of these peptides into foods provides an opportunity to 48 
support physiological functions beyond that of nutrition.  49 
Eggs are a highly nutritious food and a key dietary source of high biological protein.  It has been observed 50 
that the consumption of an egg protein-derived hydrolysate compared to the original egg protein may demonstrate 51 
greater bioactivity.  Miguel et al. [9, 10] reported that in spontaneous hypertensive rats, the long-term (20-weeks) 52 
administration of an egg-protein hydrolysate showed a clear impact on BP, whereas egg white protein 53 
demonstrated no extensive biological effects.  Interestingly, animal trials using egg-white derived peptide 54 
hydrolysate fractions have demonstrated reductions in arterial pressure in spontaneously hypertensive rats [9, 11], 55 
with no effect in normotensive rats [12].  Plat et al. [13] have recently demonstrated a BP-lowering effect of an 56 
egg-white derived peptide from the protein lysozyme in a sample of mildly hypertensive adults; however, human 57 
studies investigating peptides isolated from the egg white protein, ovalbuminin, on BP and cardiovascular risk are 58 
lacking. 59 
This is the first randomised placebo controlled trial with a crossover design to investigate the efficacy of an egg 60 
ovalbumin-derived protein hydrolysate fraction on BP and cardiovascular risk in adults with a high-normal 61 
systolic BP. 62 
 63 
Materials and Methods 64 
Study population 65 
Participants were recruited from the free-living community in the city of Cork, Republic of Ireland, via flyers and 66 
advertisements in local newspapers.  From a total of 310 volunteers who were phone-screened, 208 attended a 67 
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screening visit; of these 75 adults (41 male; 34 female) met the inclusion criteria and were enrolled onto the study 68 
protocol.  The participant flow from screening to final analysis is described in Fig 1. 69 
Participants were included if they met the following criteria: aged 50-70 yrs; in good health; had a systolic 70 
BP: 130 – ≤150 mmHg (office BP, average of 3 readings taken after 5 minutes rest (Omron 705IT monitor, 71 
ProMed, Ireland)); had a BMI: 25.0 – 35.0 kg/m2.  Main exclusion criteria included: smoking, hypertension, 72 
depressed or elevated BP measurements (systolic/diastolic: <95/55 mm Hg or >150/90 mm Hg), history of 73 
cardiovascular events, medical illness including diabetes mellitus (Types 1 & 2), egg allergy, chronic kidney 74 
disease and gastro-intestinal diseases, and medication use that may affect outcomes: anti-hypertensive 75 
medications and lipid lowering therapies. 76 
The study protocol was approved by the Clinical Research Ethics Committee of the Cork Teaching 77 
Hospitals, University College Cork (UCC), Ireland (Ref ECM 4(u) 06/08/13) and was conducted in accordance 78 
with the principles of Good Clinical Practice and the Declaration of Helsinki.  Detailed information about the 79 
study was provided to all volunteers, eligible volunteers provided their written informed consent at screening.  80 
This trial was registered at clinicaltrials.gov: Identifier NCT02223169/ 81 
 82 
Study design 83 
This study was a double-blind, randomized, placebo-controlled crossover trial with two 6-week periods separated 84 
by a 3-week washout (Online resource 2).  Participants completed a 2-week run-in prior to commencing the trial.  85 
Enrolled volunteers were randomly assigned to their treatment using a block randomization scheme.  Separate 86 
randomization schedules were generated for men and women.  The randomization process and treatment 87 
allocation was conducted by a senior scientist not involved in the implementation or analysis of the trial.  For the 88 
research team, a double-blinded protocol was maintained for the duration of the study and analysis. 89 
At baseline, participants received 42 blinded sachets in a sealed envelope.  Participants were randomized 90 
in a 1:1 ratio to receive either the active treatment (powdered egg ovalbumin-derived protein hydrolysate fraction, 91 
3g/d) or placebo-control (maltodextrin powder, 3g/d) for 6 weeks (period 1), after washout, participants received 92 
the alternative intervention for a further 6-weeks (period 2), followed by a final 3-week washout.  The duration of 93 
the washout was in line with other peptide dietary intervention studies [14, 15].   94 
 The primary outcome was systolic BP (by office and central measurement); secondary outcomes 95 
included diastolic BP, changes in arterial stiffness (assessed by augmentation index by pulse wave analysis (PWA) 96 
and carotid-femoral, pulse wave velocity (cfPWV), fasting plasma lipids and glucose concentrations. 97 
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 98 
Study treatments 99 
The egg ovalbumin-derived protein hydrolysate fraction (3g/d) and matching placebo (maltodextrin, 3g/d) were 100 
produced by BioActor, The Netherlands, in a plant (Bouwhuis Enthoven) which complies with food-grade 101 
conditions.  Both powders were manufactured to appear and taste similar.  Participants consumed one sachet each 102 
morning as part of a meal.  Participants were instructed to add their sachet to a fruit juice (~150 mL) and to mix 103 
prior to consumption using the beverage shaker provided.  The energy content of the egg albumin-derived protein 104 
hydrolysate fraction and the maltodextrin sachets were 1584 kJ/100g and 1757 kJ/100g, respectively (for nutrient 105 
compositions, see Online resource 1).  A full characterization of these egg-derived protein hydrolysates as well as 106 
an in vitro evaluation of their ACE-inhibitory activity was undertaken prior to study commencement by BioActor 107 
(Table 1).  For potential mechanistic data underpinning the biological activity of this peptide digestate fraction, 108 
the manufacturers measured angiotensin converting enzyme inhibition (IACE) as well as anti-oxidant activity of 109 
the egg ovalbumin-derived protein hydrolysate fractions using an Oxygen Radical Absorbance Capacity (ORAC) 110 
assay, prior to trial commencement.  The ACE inhibitory activity (µM) and antioxidant capacity (µmoleq Trolox) 111 
were directly comparable to data reported by Miguel et al. [16] and Davalos et al. [17].  The in vitro digestion and 112 
bioavailability of the egg-albumin derived protein hydrolysate fractions used in the current study are 113 
comprehensively described by Grootaert et al. [18]]. 114 
In terms of safety, a number of animal studies were published in which egg albumin-derived peptide 115 
hydrolysates were administered without adverse events [9, 11, 19-20].  In addition, a pilot safety study at a similar 116 
level of supplementation (3g) of this specific egg ovalbumin-derived protein hydrolysate digestate fraction was 117 
conducted in adults (n 20); where, no adverse events (AE) associated with consumption were observed.  In the 118 
current study, the occurrence of any potential AE was checked routinely by the research team. Any AE 119 
experienced during the study were documented in detail on a clinical report form and reported to the Ethics 120 
Committee for the project and the Principal Investigator who assessed the relation of the AE to the treatment.  121 
Participant compliance was assessed by counting the used and remaining sachets a participant returned.  122 
 123 
Study visits 124 
Study visits took place at the Human Nutrition Studies Unit at UCC between May 2014 and February 2016.  125 
Participants were requested to maintain their habitual diet, level of physical activity and body weight.  Participants 126 
were asked to refrain from consuming eggs and egg dishes for the study duration.  Participants were monitored to 127 
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encourage compliance with the protocol.  At screening, data on BP, weight and height were collected.  Participants 128 
attended the study unit in a fasted state between 08:00 and 10:00 am at the baseline and endpoint of each study 129 
period and post the final washout (5 sampling points).  Measurement of office and central BP, arterial stiffness 130 
and anthropometric assessements were completed at each visit.  Health and lifestyle information were also 131 
collected. 132 
 133 
BP 134 
BP was measured in accordance with the European Society of Hypertension guidelines [21].  Office BP was 135 
measured on fasted study-participants, between 08:00 – 10:00 am, prior to blood sampling, on the same arm at 136 
each visit and in accordance with a standardised protocol.  BP was measured after the participant was in a seated 137 
position in a quiet room for at least 5 minutes.  Office BP was measured 3 times with using a validated 138 
oscillometric semiautomatic arm device (Omron 705IT monitor) with 2-3 minute intervals between readings and 139 
the mean reading was calculated. 140 
 141 
Central BP and assessment of arterial stiffness index 142 
Central BP, augmentation index by PWA and carotid-femoral cfPWV, a known indicator of arterial stiffness and 143 
cardiovascular risk, was measured with the participant in the semi-supine position using a non-invasive 144 
oscillometric technique with the Vicorder® Tonometric device (Skidmore medical, UK) (for further details see 145 
[22]). 146 
 147 
Anthropometry 148 
Height was measured using a wall-mounted stadiometer without shoes.  Body weight was measured in participants 149 
without shoes and in light clothing using a SECA weighing scales (ProMed, Ireland).  Waist circumference was 150 
measured midway between the lowest rib and the iliac crest using a SECA tape measure (ProMed, Ireland).  Body 151 
composition (fat mass and lean mass) was assessed during one visit by dual-energy X-ray absorptiometry (DXA) 152 
scan on a Lunar DXA device (GE Medical Systems, UK).   153 
 154 
Blood sampling 155 
Five fasting blood samples (30ml) were collected under standardised conditions.  For the 24 hours prior to their 156 
visit, participants refrained from alcohol consumption and strenuous physical activity.  Blood samples were 157 
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processed and immediately stored at -80°C until analysis.  Post-blood sampling participants received their 158 
breakfast. 159 
 160 
Biochemical analysis 161 
All fasting samples for each participant were analysed within the same batch.  Plasma lipids (total-cholesterol, 162 
HDL-cholesterol and triglycerides) and glucose were measured using an automated bench top clinical chemistry 163 
analyser (RX Autoanalyser, Randox laboratories, NI) according to the manufacturer’s instructions.  The co-164 
efficient of variation (CV) for inter –day variations was <10%.  LDL-cholesterol was estimated using Friedewald’s 165 
formula [23]. 166 
 167 
Sample size calculation 168 
Sample size was calculated based on systolic BP data derived from baseline values of 700 adults who had 169 
previously participated in RCTs at UCC.  This study was powered to detect a reduction of 2 mmHg systolic BP 170 
at 80% power and with a significance level of 5%, and a within-subject standard deviation of 4.0 mmHg.  In total 171 
65 participants were required to complete the study, rounded up to 33 per group.  Anticipating a 20% dropout rate, 172 
we aimed to randomly allocate 78 participants. 173 
 174 
Statistical analysis 175 
Statistical analyses were performed using IBM SPSS statistical software package (Version 23).  Analyses are 176 
presented on a per-protocol basis; intention-to-treat (ITT) analysis is included as a Review Table for informational 177 
purposes (Online resource 3).  Findings were similar between both analyses.  Variables were tested using Shapiro 178 
Wilks test to establish whether data followed a parametric or non-parametric distribution.  Plasma HDL 179 
cholesterol and triglyceride concentrations assumed a parametric distribution once log-transformed.   180 
As no treatment carryover effects were observed between the two study periods, data were subsequently 181 
analysed as a total group.  Differences between sexes at baseline were tested using an independent student’s t test.  182 
Similarly, differences in baseline values between treatment groups were compared using an independent student’s 183 
t test.  Intra-group differences (baseline v. endpoint) were performed using a paired student’s t test.  Inter-group 184 
comparisons (changes during egg-protein hydrolysate treatment v. changes during placebo treatment) of normally 185 
distributed data were performed using an independent student’s t test and were also evaluated using a general 186 
linear model (GLM) ANCOVA, with mean change (post-minus-baseline) in the variable as the dependent factor, 187 
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study treatment as the fixed factor.  Potential confounding factors including the baseline values of the dependent 188 
variable, age, gender, and waist circumference were added to the model.  A P-value ≤ 0.05 was considered as 189 
statistically significant. 190 
 191 
Results 192 
Study participation 193 
Of the 75 volunteers enrolled onto the study, 68 completed the protocol (Fig 1).  One participant failed to 194 
commence the study.  Six study participants withdrew from the study for a variety of reasons: one participant had 195 
elevated BP measures during their visit and were advised to attend their Physican; one participant developed 196 
urticaria and was advised by their Physican to withdraw from the study; two participants did not attend visits and 197 
were uncontactable, and the remainder withdrew for personal reasons.  There were two potential AEs, although 198 
not confirmed to be associated with the intervention.  While 68 participants completed the study, three participants 199 
were subsequently excluded from the analysis: one commenced anti-hypertensive therapy, another commenced a 200 
cholesterol-lowering medication, and a third participant was removed due to poor compliance.  This analysis 201 
includes data from 65 participants (37 male, 28 female).  Overall, counts of returned sachets indicated a 94.1 (SD 202 
11)% and 93.0 (SD 11.0)% compliance with egg-protein hydrolysate and placebo consumption, respectively.  203 
Specifically, in period 1, counts of returned sachets indicted a 95.1 (SD 8)% and 95.2 (SD 10)% compliance for 204 
egg-protein hydrolysate and placebo consumption, respectively, and in period 2, a 93.2 (SD 12)% and 90.6 (SD 205 
11)% compliance for egg-protein hydrolysate and placebo consumption, respectively. 206 
 207 
Baseline characteristics 208 
Baseline characteristics after the 2-week run-in period are summarised in Table 2.  Gender differences for office 209 
systolic BP, cfPWV, body weight, height, fat free mass and waist circumference were observed, where men had 210 
significantly higher values (P<0.05) compared to women.  Women had significanty higher (P<0.05) values for 211 
PWA augmentation index (%) and concentrations of HDL-cholesterol compared to men.  No significant 212 
differences in baseline values were observed for any variable between the egg-protein hydrolysate and placebo 213 
groups (P >0.05). 214 
 215 
Effect of egg-protein hydrolysate supplementation on BP and arterial stiffness index 216 
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Office and central systolic BP and diastolic BP and cfPWV did not significantly change over time (Table 3).  PWA 217 
augmentation index (%) increased slightly in the placebo group (P = 0.056).  No significant differences for mean 218 
changes in office or central BP, cfPWV or PWA were observed between the egg-protein hydrolysate and the 219 
placebo groups accounting for baseline levels of the variable, age, gender and waist circumference.  A sub-group 220 
analysis stratified by gender also indicated no differences in the response of men and women to the treatments 221 
(data not shown). 222 
Due to the variability in BP over the course of the study, a sub-group analysis stratifying participants 223 
according to their baseline BP values (group 1: normotensive participants with a systolic BP < 140 mm Hg and a 224 
diastolic BP < 90 mm Hg and group 2: hypertensive participants with a systolic BP ≥140 mm Hg and /or a diastolic 225 
BP ≥90 mm Hg) is presented in Table 4.  There was no effect of treatment for systolic BP, PWA or cfPWV in the 226 
normotensive or hypertensive group.  In the egg-protein hydrolysate group, hypertensive participants showed a 227 
non-significant reduction in systolic BP (~-2.2 mm Hg; P >0.1); while in normotensive participants, systolic BP 228 
appeared to increase (+3.6 mm Hg, P <0.05). 229 
 230 
Effect of egg-protein hydrolysate supplementation on biomarkers of cardiovascular risk 231 
In the egg-protein hydrolysate and placebo groups, concentrations of fasting glucose, triglycerides and LDL-232 
cholesterol (all secondary outcomes) did not significantly change over time (Table 3).  In the placebo group, but 233 
not in the egg-protein hydrolysate group, concentrations of HDL- (P = 0.001) and total-cholesterol (P = 0.032) 234 
increased significantly over the 6-weeks.  No significant differences for the mean changes in concentrations of 235 
fasting glucose, total and LDL-cholesterol and triglycerides between the egg-protein hydrolysate and the placebo 236 
groups were observed adjusting for the baseline value, age, gender and waist circumference. 237 
 238 
Effect of egg-protein hydrolysate supplementation on body weight and waist circumference 239 
A modest increase in body weight and BMI (P<0.05) was observed in the egg-protein hydrolysate group over the 240 
6-week intervention (mean increase in body weight: 0.4 [95% CI: 0.1, 0.7] kg and mean increase in BMI: 0.1 241 
[95%CI: 0.01, 0.2] kg/m2).  However, these increases were not significantly different (P > 0.3) from the smaller 242 
and non-significant increases observed for the placebo group. 243 
 244 
 245 
 246 
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Discussion 247 
We investigated for the first time the effects of an egg white, ovalbumin-derived protein hydrolysate on BP, 248 
arterial stiffness and markers of CVD risk in adults with a mildly elevated systolic BP.  Our findings indicate that 249 
supplementation with 3g/d of an ovalbumin protein hydrolysate fraction for 6-weeks does not lower BP, improve 250 
arterial stiffness or modify biomarkers of cardiovascular risk.  In contrast, to the best of our knowledge, the only 251 
other dietary intervention study in humans investigated the effects of a different egg-white derived peptide from 252 
the protein lysozyme on BP [13].  This dose-finding study demonstrated significant reductions in daytime SBP 253 
and DBP in participants with mild hypertension but no effect on BP was observed in participants with a normal 254 
or high-normal BP [13].  In the current study, participants were not hypertensive with a mean (SD) baseline SBP 255 
of 136 (12) mm Hg and DBP of 89 (6) mm Hg, respectively. 256 
Recent systematic reviews and meta-analyses have demonstrated positive effects of bioactive peptides 257 
particularly lactotripeptides on BP [7-8; 24-25].  These effects appear dependent on baseline BP [7] and ethnicity, 258 
with Asian subjects demonstrating a greater response for BP when compared to caucasian subjects [7, 26].  In the 259 
current study, the principal screening criterion was a mean office systolic BP 130 – 149 mmHg.  While we aimed 260 
to rule-out “white-coat” hypertension by conducting measurements in accordance with best practice guidelines 261 
[21]; readings for systolic BP <130 mmHg were observed at baseline in some participants.  The inclusion of 262 
repeated screenings for BP may have reduced the variability for BP in our sample [21] and the likelihood of 263 
including normotensive participants.  Trials with dairy peptides reporting reductions in systolic BP have generally 264 
included adults with higher baseline BP values compared to the current study [27 – 30] which may partially 265 
explain the lack of effect observed.  Potential acute effects of this ovalbumin-derived protein hydrolysate fraction 266 
on BP were not measured in the current study. 267 
A strength of the current study was the measurement of both peripheral (office) and central BP which 268 
was assessed by PWA.  Data indicate that aortic or central pressure is more strongly related to future 269 
cardiovascular events than peripheral pressure [31, 32].  We did not observe an effect of this egg protein 270 
hydrolysate fraction on arterial stiffness (PWA augmentation index or PWV).  While improvements in PWV 271 
measures after 6 weeks of lactotripeptide consumption have been reported [33]; Jauhiainen et al. [34] observed 272 
reductions in PWA augmentation index after lactotripeptide consumption in a 12-week trial.  This may indicate 273 
that an intervention period greater than 6-weeks is required to observe significant changes in arterial stiffness, 274 
however, considering the crossover nature of the current trial, maintaining participant compliance for longer 275 
periods may have become an issue. 276 
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 277 
Animal and in vitro evidence have postulated three potential mechanisms by which the ovalbumin –278 
derived protein hydrolysate fractions may exert their BP lowering effects; angiotensin-converting enzyme (ACE)-279 
inhibition [9, 10; 19, 35], nitric oxide (NO)-mediated vasodilation [11, 36] and increased antioxidant capacity 280 
[37].  The clinical efficacy of peptides depends on two critical factors: their resistance to degradation by gastro-281 
intestinal peptidases and their absorption into the blood stream in sufficient quantities [6, 38].  In the current trial, 282 
the bioactivity of this egg ovalbumin-derived protein hydrolysate fraction, in terms of anti-hypertensive activity 283 
was confirmed prior to study commencement.  Furthermore, in vitro research describing a methodology for 284 
quantifying these egg-protein hydrolysates and the application to quantify the survival of the ACE-inhibitory 285 
peptides in these protein hydrolysate fractions in the gastro-intestinal tract were undertaken as part of this study 286 
[18].  Gastro-intestinal digestion is not always sufficient for optimal release and stability of bioactive fragments 287 
from the original protein structure [38].  In this context, the interference of food matrix constituents with bioactive 288 
peptide release and bioavailability are also important considerations, although this aspect is generally overlooked 289 
when developing peptide-containing hydrolysate based functional foods [18].  We were unable to establish a 290 
reliable biomarker of exposure to assess compliance with study treatments due to the established short half-lives of 291 
these peptides [39].  This is partially attributable to the limited availability of analytical protocols for the 292 
quantification of functional peptides in complex foods and physiologically relevant matrices. 293 
This ovalbumin-derived protein hydrolysate fraction did not significantly modify concentrations of 294 
plasma total-, HDL- or LDL-cholesterol, triglycerides or plasma glucose.  Animal and in vitro data have indicated 295 
potential benefits of soy, lupin and milk peptides for reducing LDL-cholesterol [6].  While studies investigating 296 
the effects of egg-peptides on blood lipids are limited, Manso et al. [37] observed significant reductions in total-297 
cholesterol and triglyceride concentrations in spontaneously hypertensive rats fed egg-white hydrolysates.  While 298 
modest increases in HDL- and total-cholesterol were observed in the placebo group, there were no corresponding 299 
changes in body weight. 300 
The current study benefitted from its robust study design (a randomised double-blind, placebo-controlled 301 
crossover trial) that was suitably-powered with a six-week treatment duration; other studies to date have included a 302 
four-week treatment duration [15, 27, 28].  Considering the crossover nature, dropout rates were low and 303 
compliance with the treatments was good.  The absence of dietary data, in particular for protein intake, to inform 304 
on background habitual diet is a limitation of the current study.  While a supplemental dose of 3g protein per day 305 
was provided as the study treatment to participants, this quantity of protein could be deemed as modest when 306 
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reflected in the context of total protein intake and should not influence total dietary intake.  Findings from a sub-307 
analysis stratified by gender did not differ from the findings of the whole-group.  Similarly, other inteventions 308 
with bioactive peptides have reported no difference in treatment responses between men and women [15, 27]. 309 
The appropriate selection of a food matrix for the delivery of study treatments is crucial.  Participants 310 
mixed their study treatments with a fruit juice (predominantly orange juice).  Sensory analysis prior to the study 311 
indicated that fruit juice was a suitable matrix for masking the bitter taste associated with the ovalbumin-derived 312 
protein hydrolysate.  While a separate assessment of the bioavailability of this protein hydrolysate within a fruit 313 
juice matrix was not conducted; findings from other trials where dairy protein hydrolysates were incorporpated 314 
with fruit juices have also indicated a lack of effect on clinical outcomes, particulary for BP [14], which questions 315 
the suitability of fruit juice as a food vehicle for bioactive peptides.  316 
 317 
Concluding remarks 318 
Increasing consumer knowledge of the link between diet and health has raised the demand for food ingredients 319 
with scientifically proven health benefits.  A reduction of 3 mm Hg in systolic BP has been estimated to reduce 320 
coronary heart disease by 5-9%, stroke by 8-14%, and all-cause mortality by 4% [40], thus, bioactive peptides 321 
with proven anti-hypertensive activity, consumed as part of a healthy diet, may be of functional interest in both 322 
the treatment and prevention of hypertension.  This is the first study to investigate and show that supplementation 323 
with an egg ovalbumin-derived protein hydrolysate fraction for 6-weeks does not lower BP or improve markers 324 
of CVD risk.  Well-designed dietary interventions which consider not only the variability in baseline BP values 325 
and ethnicity; but also the suitability of the food matrix and timing of delivery are warranted to further elucidate 326 
the biological functions of egg-derived components. 327 
 328 
Author contributions: MEK, AJL and PAK designed the study; MEK and AJL monitored the study, CH, EM and 329 
AJL conducted study visits, biochemical analysis and data-entry.  AJL and MEK analyzed and interpreted the 330 
data and wrote the manuscript.  PAK modified the writing of the manuscript and read and approved the final 331 
manuscript. 332 
 333 
Acknowledgement: The authors thank all volunteers for participating in the study, and Dr Charlotte Grootaert 334 
(Dept of Food Safety and Food Quality, Ghent University, Belgium) and Dr Stefan Vorspooels (Flemisch Institute 335 
13 
 
for Technological Research), Belgium for informing on the in vitro stability of this egg ovalbumin-derived peptide 336 
digestate fraction. 337 
 338 
This RCT was part of the EC funded BACCHUS [Beneficial effects of dietary bioactive peptides and polyphenols 339 
on cardiovascular health in humans] project (http://www.bacchus-fp7.eu/) which received funding from the 340 
European Union Seventh Framework Programme (FP7/2007-2013) under Grant Agreement no 321090.  PAK 341 
received additional support from the Biotechnology and Biological Sciences Research Council (Food and Health 342 
Institute Strategic Programme Grant, BB/J004545/1). 343 
The authors have declared no conflicts of interest. 344 
  345 
14 
 
References 346 
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK et al. (2016) Heart Disease and Stroke Statistics—2016 347 
Update. Rep Am Heart Assoc. 133: e38-e360. 348 
2. Landsberg L, Aronne LJ, Beilin LJ, Burke V, et al. (2013) Obesity-Related Hypertension: Pathogenesis, 349 
Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of 350 
Hypertension. J Clin Hypertens 15: 14-33. 351 
3. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, et al. (1997)  A Clinical Trial of the Effects of Dietary 352 
Patterns on Blood Pressure. New Engl J Med 336: 1117-1124. 353 
4. Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. (2014) Influence of Dietary Approaches to 354 
Stop Hypertension (DASH) diet on blood pressure: A systematic review and meta-analysis on randomized 355 
controlled trials. Nutr Metab Cardiovas 24: 1253-1261. 356 
5. Hernández-Ledesma B, Del Mar Contreras M, Recio, I. (2011) Antihypertensive peptides: Production, 357 
bioavailability and incorporation into foods. Adv Colloid Interface Sci 165: 23-35. 358 
6. Cicero AFG, Fogacci F, Colletti A. (2017) Potential role of bioactive peptides in prevention and treatment of 359 
chronic diseases: a narrative review. Br J Pharmacol. 174: 1378-1394. 360 
7. Cicero AFG, Gerocarni B, Laghi L, Borghi C. (2011) Blood pressure lowering effect of lactotripeptides 361 
assumed as functional foods: A meta-analysis of current available clinical trials. J Hum Hypertens 25: 425-362 
436. 363 
8. Pripp AH (2008) Effect of peptides derived from food proteins on blood pressure: A meta-analysis of 364 
randomized controlled trials. Food Nutr Res 52: 10.3402/fnr.v52i0.1641 365 
9. Miguel M, Manso MA, Martín-Álvarez PJ, Aleixandre A et al. (2007) Angiotensin-converting enzyme 366 
activity in plasma and tissues of spontaneously hypertensive rats after the short- And long-term intake of 367 
hydrolysed egg white. Mol Nutr Food Res 51: 555-563. 368 
10. Miguel M, López-Fandiño R, Ramos M, Aleixandre A. (2006) Long-term intake of egg white hydrolysate 369 
attenuates the development of hypertension in spontaneously hypertensive rats. Life Sci 78: 2960-2966. 370 
11. Garcia-Redondo AB, Roque FR, Miguel M, López-Fandiño R. et al. (2011) Vascular effects of egg white-371 
derived peptides in resistance arteries from rats. Structure-activity relationships. J Sci Food Agr 90: 1988-372 
1993. 373 
12. Miguel M, López-Fandiño R, Ramos M, Aleixandre A. (2005) Short-term effect of egg-white hydrolysate 374 
products on the arterial blood pressure of hypertensive rats. Br J Nutr 94: 731-737. 375 
15 
 
13. Plat J, Severins N, Morrison S, Mensink RP (2017) Effects of NWT-03, an egg-protein hydrolysate, on blood 376 
pressure in normotensive and mildhypertensive men and women: a dose-finding study. Br J Nutr 117: 942-377 
950. 378 
14. Cicero AF, Rosticci M, Veronesi M, Bacchelli S, et al., (2010) Hemodynamic effects of lactotripeptides from 379 
casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a 380 
randomized, double-blind, crossover clinical trial. J Med Food 13: 1363-1368. 381 
15. Van Mierlo LA, Koning MMG, Van Zander KD, Draijer R. (2009) Lactotripeptides do not lower ambulatory 382 
blood pressure in untreated whites: Results from 2 controlled multicenter crossover studies. Am J Clin Nutr 383 
89: 617-623. 384 
16. Miguel M, Recio I, Gomez-Ruiz JA, Ramos M, Lopez-Fandino R. (2004) Angiotensin I-converting enzyme 385 
inhibitory activity of peptides derived from egg white proteins by enzymatic hydrolysis. J Food Prot. 67: 386 
1914-1920. 387 
17. Davalos A, Miguel M, Bartolome B, Lopez-Fandino R. (2004) Antioxidant activity of peptides derived from 388 
egg white proteins by enzymatic hydrolysis. J Food Prot 67:1939-44. 389 
18. Grootaert CJG, Matthijs B, Pitart J, Baggerman G. et al. (2017) Quantificant of egg ovalbumin hydrolysate-390 
derived anti-hypertensive peptides in an in vitro model combining luminal digestion with intestinal Caco-2 391 
cell transport. Food Res Int 99: 513-541. 392 
19. Miguel M, Aleixandre A. (2006) Antihypertensive peptides derived from egg proteins. J Nutr 136: 1457-393 
1460. 394 
20. Miguel M, Manso M, Aleixandre A, Alonso MJ, et al. (2007) Vascular effects, angiotensin I-converting 395 
enzyme (ACE)-inhibitory activity, and antihypertensive properties of peptides derived from egg white. J Agr 396 
Food Chem 55: 10615-10621. 397 
21. Mancia G, Fagard R, Narkiewicz K, Redon J, et al. (2014) 2013 ESH/ESC Practice Guidelines for the 398 
Management of Arterial Hypertension. Blood Pressure 23: 3-16. 399 
22. Laurent S, Marais L, Boutouyrie P. (2016) The Noninvasive Assessment of Vascular Aging. Can J Cardiol 400 
32: 669-679. 401 
23. Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the Concentration of Low-Density 402 
Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem 18: 499-502. 403 
16 
 
24. Cicero AFG, Aubin F, Azais-Braesco V, Borghi C. (2013) Do the Lactotripeptides Isoleucine–Proline–404 
Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis 405 
of Randomized Controlled Trials. Am J Hypertens 26: 442-449. 406 
25. Fekete ÁA, Givens DI, Lovegrove JA. (2015) Casein-derived lactotripeptides reduce systolic and diastolic 407 
blood pressure in a meta-analysis of randomised clinical trials. Nutrients 7: 659-681. 408 
26. Fekete ÁA, Givens DI, Lovegrove JA. (2016) Can milk proteins be a useful tool in the management of 409 
cardiometabolic health? An updated review of human intervention trials. Proc Nutr Soc 75: 328-341. 410 
27. Boelsma E, Kloek J. (2010) IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 411 
hypertension, a randomized controlled trial. Nutr J. 9:52. 412 
28. Cicero AFG, Colletti A, Rosticci M, Cagnati M, et al. (2016) Effect of Lactotripeptides (Isoleucine-Proline-413 
Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with 414 
Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover 415 
Clinical Trial. Metab Syndr Rel Disord 14: 161-166. 416 
29. Seppo L, Jauhiainen T, Poussa T, Korpela R. (2003) A fermented milk high in bioactive peptides has a blood 417 
pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77: 326-330. 418 
30. Turpeinen AM, Ehlers PI, Kivimäki AS, Järvenpää S. et al. (2011) Ile-Pro-Pro and Val-Pro-Pro tripeptide-419 
containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects. Clin Exp 420 
Hypertens 33: 388-396. 421 
31. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, et al. (2014) Central blood pressure: current evidence 422 
and clinical importance. Eur Heart J 35: 1719-1725. 423 
32. Roman MJ, Devereux RB, Kizer JR, Okin PM, et al. (2009) High Central Pulse Pressure Is Independently 424 
Associated With Adverse Cardiovascular Outcome: The Strong Heart Study. J Am Coll Cardiol 54: 1730-425 
1734. 426 
33. Cicero AFG, Rosticci M, Gerocarni B, Bacchelli S, et al. (2011) Lactotripeptides effect on office and 24-h 427 
ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients 428 
with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. 429 
Hypertens Res. 34: 1035-1040. 430 
34. Jauhiainen T, Ronnback M, Vapaatalo H, Wuolle K, et al. (2010) Long-term intervention with Lactobacillus 431 
helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr 64: 424-431. 432 
17 
 
35. Miguel M, Alonso MJ, Salaices M, Aleixandre A, et al. (2007) Antihypertensive, ACE-inhibitory and 433 
vasodilator properties of an egg white hydrolysate: Effect of a simulated intestinal digestion. Food Chem 104: 434 
163-168. 435 
36. Miguel M, Alvarez Y, López-Fandiño R, Alonso MJ, et al. (2007) Vasodilator effects of peptides derived 436 
from egg white proteins. Regul Peptides 140: 131-135. 437 
37. Manso MA, Miguel M, Even J, Hernández R, et al. (2008) Effect of the long-term intake of an egg white 438 
hydrolysate on the oxidative status and blood lipid profile of spontaneously hypertensive rats. Food Chem 439 
109: 361-367. 440 
38. Liu YF, Oey I, Bremer P, Carne A, Silcock P. (2017) Bioactive peptides derived from egg proteins: A review. 441 
Crit Rev Food Sci 13:1-23. 442 
39. Sato K, Urado D. (2015) in Detection and Identification of Food-Derived Peptides in Human Blood: Food-443 
Derived Short Chain Peptidomes in Human Blood, in Genomics, Proteomics and Metabolomics in 444 
Nutraceuticals and Functional Foods: Second Edition, pp. 441-452. 445 
40. Rosendorff C, Black CP, Cannon BJ, Gersh, et al. (2007) Treatment of hypertension in the prevention and 446 
management of ischemic heart disease: A scientific statement from the American Heart Association council 447 
for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. 448 
Circulation 115: 2761-2788. 449 
 450 
18 
 
Table 1: Key peptides present in egg ovalbumin-derived protein hydrolysate fraction. 
 
a Bioactivity of peptides was determined based on previously published studies 
  
Peptides present Antihypertensive activity  
Antioxidant activity 
(by ORAC-Fl assay) References 
Whole hydrolysate  
(Egg ovalbumin-derived peptide 
digestate fraction used in study) 
ACE-inhibitory activity 
 
In vitro radical scavenging 
 
In house data produced by BioActor 
 
FRADHPFLa ACE-inhibitory activity In vitro radical scavenging Miguel et al. [16, 35] Dávalos et al. [17] 
RADHPFLa ACE-inhibitory activity In vitro radical scavenging 
Miguel et al. [16, 35] 
Dávalos et al. [17] 
Grootaert et al. [18] 
YAEERYPILa ACE-inhibitory activity In vitro radical scavenging  
Miguel et al. [16, 35] 
Dávalos et al. [17] 
Grootaert et al. [18] 
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Table 2. Participant characteristics at the baseline visit during period 1 
  Total (n 65) Men (n 37 ) Women (n 28) P a 
Age (y) 56.9 ± 5.2 57.1 ± 5.4 56.6 ± 4.4 0.734 
Systolic BP (mmHg) (Office) 136.3 ± 12.1 140.1 ± 11.9 131.2 ± 10.6 0.003 
Diastolic BP (mmHg) (Office) 88.9 ± 6.4 89.3 ± 6.0 88.3 ± 6.9 0.562 
Systolic BP (mmHg) (Central) 135.1 ± 11.9 135.1 ± 12.0 134.9 ± 11.9 0.953 
Diastolic BP (mmHg) (Central) 75.5 ± 6.4 76.3 ± 6.1 74.3 ± 6.6 0.215 
PWV (m/s) 9.1 ± 1.3 9.4 ± 1.4 8.7 ± 1.2 0.035 
PWA (AI %) 27.6 ± 6.2 25.2 ± 5.5 30.7 ± 5.7 <0.001 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 <0.001 
Body weight (kg) 81.1 ± 13.0 86.6 ± 12.3 73.8 ± 10.0 <0.001 
BMI (kg/m2) 28.3 ± 3.5 28.2 ± 3.3 28.3 ± 3.8 0.930 
Body fat (%)b 34.5 ± 7.8 29.5 ± 5.6 40.9 ± 5.1 <0.001 
Fat free mass (kg)b 51.0 ± 10.1 58.3 ± 6.6 41.6 ± 4.2 <0.001 
Waist circumference (cm) 94.0 ± 10.2 97.3 ± 9.6 89.7 ± 9.4 0.002 
Total cholesterol (mmol/L) 5.57 ± 0.9 5.48 ± 0.9 5.69 ± 0.9 0.408 
HDL- cholesterol (mmol/L) 1.47 ± 0.6 1.33 ± 0.6 1.67 ± 0.7 0.035 
LDL-cholesterol (mmol/L) 3.58 ± 0.9 3.57 ± 0.9 3.59 ± 0.9 0.919 
Triglycerides (mmol/L) 1.29 ± 1.5 1.56 ± 1.9 0.95 ± 0.4 0.119 
Glucose (mmol/L) 5.49 ± 0.6 5.59 ± 0.6 5.35 ± 0.7 0.155 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as Mean ± SD (all such values) 
BP, blood pressure; PWV, pulse wave velocity; PWA, pulse wave analysis; AI, augmentation index  
a Independent student’s t test 
b Measured by DXA scan during one study visit 
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Table 3. Measures of blood pressure and cardiovascular risk stratified by treatment allocated in 65 men and women 
  
 
 Ovalbumin egg-protein hydrolysate (n 65)   Placebo (n 65)      
  Baseline Endpoint Mean changea (95% CI) Pb   Baseline Endpoint Mean changea (95% CI) Pb Pc Pd 
Systolic BP* 
(mmHg) (Office) 132.5 ± 12.6 132.8 ± 12.1 -0.2 (-2.8, 2.3) 0.867  134.4 ± 10.7 131.6 ± 11.5 -1.3 (-3.9, 1.4) 0.344 0.472 0.471 
Diastolic BP* 
(mmHg) (Office) 87.7 ± 7.0 88.3 ± 7.9 0.6 (-0.9, 2.0) 0.447  88.1 ± 8.0 87.0 ± 8.1 -0.5 (-2.2, 1.1) 0.528 0.328 0.309 
Systolic 
BP*(mmHg) 
(Central) 135.5 ± 12.3 134.8 ± 10.6 -0.8 (-3.7, 2.1) 0.478  133.8 ± 10.6 132.7 ± 10.7 -0.5 (-3.3, 2.2) 0.679 0.820 0.660 
Diastolic BP* 
(mmHg) 
(Central) 75.9 ± 6.3 75.9 ± 6.2 -0.4 (-1.9, 1.1) 0.885  76.1 ± 7.0 75.4 ± 8.6 -0.6 (-2.5, 1.2) 0.446 0.933 0.857 
PWV (m/s) 9.1 ± 1.5 9.2 ± 1.3 0.04 (-0.3, 0.4) 0.570  9.3 ± 1.2 9.3 ± 1.4 0.06 (-0.3, 0.4) 0.522 0.888 0.968 
PWA (AI %) 27.8 ± 6.7 27.8 ± 7.8 -0.02 (-1.6, 1.5) 0.955  26.8 ± 6.3 28.9 ± 8.5 1.8 (0.01, 3.6) 0.056 0.142 0.093 
 
Total cholesterol 
(mmol/L) 5.67 ± 1.1 5.69 ± 1.0 0.03 (-0.2, 0.2) 0.747  5.65 ± 1.0 5.91 ± 1.1 0.3 (0.02, 0.5) 0.032 0.146 0.147 
HDL-cholesterol 
(mmol/L) 1.54 ± 0.6 1.56 ± 0.6 0.02 (-0.1, 0.1) 0.703  1.48 ± 0.6 1.66 ± 0.6 0.2 (0.1, 0.2) 0.001 0.077 0.076 
LDL-cholesterol 
(mmol/L) 3.65 ± 0.9 3.58 ± 0.9 -0.1 (-0.3, 0.1) 0.364  3.62 ± 0.9 3.71 ± 0.9 0.1 (-0.1, 0.3) 0.361 0.281 0.288 
Triglycerides 
(mmol/L) 1.10 ± 0.6 1.19 ± 0.6 -0.02 (-0.3, 0.2) 0.841  1.21 ± 0.6 1.18 ± 0.5 -0.03 (-0.2, 0.1) 0.712 0.982 0.955 
Glucose  
(mmol/L) 5.55 ± 0.8 5.61 ± 0.8 0.04 (-0.2, 0.2) 0.710   5.67 ± 0.8 5.62 ± 0.9 -0.04 (-0.3, 0.2) 0.766 0.642 0.533 
Mean ± SD (all such values); *Primary outcome BP: BP, blood pressure; PWV, pulse wave velocity; PWA, pulse wave analysis; AI, augmentation index 
a Mean change (Post-intervention – baseline) 
b P for Intra (within) -group comparison (Paired student’s t test) 
c P for Inter (between) -group comparison (Independent student’s t test) 
d P for Inter-group comparison (GLM ANCOVA model adjusted for baseline value for the dependent variable, gender, age and waist circumference) 
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Table 4. Measures of blood pressure, pulse wave velocity and pulse wave analysis stratified by treatment allocated and the presence or absence of hypertension 
 Ovalbumin egg-protein hydrolysate  Placebo       
  Baseline Endpoint Mean changea (95% CI) Pb   Baseline Endpoint Mean changea (95% CI) Pb Pc Pd 
Normotensivee n 15   n 13      
SBP (mmHg) (Office) 122.5 ± 5.5 125.5 ± 8.4 3.6 (0.2, 7.0) 0.041  125.7 ± 5.8 125.1 ± 8.9 -1.7 (-6.9, 3.5) 0.505 0.191 0.164 
DBP (mmHg) (Office) 83.4 ± 4.0 84.9 ± 5.8 1.7 (-0.5, 4.0) 0.126  81.9 ± 5.5 83.2 ± 5.8 0.5 (-2.0, 3.1) 0.672 0.487 0.436 
SBP (mmHg) (Central) 130.7 ± 12.5 132.8 ±12.0 2.0 (-2.9, 7.1) 0.558  127.3 ± 10.2 127.9 ± 8.3 0.6 (-3.8, 4.9) 0.641 0.481 0.377 
DBP (mmHg) (Central) 72.0 ± 5.7 72.7 ± 3.7 0.6 (-1.5, 2.7) 0.262  73.1 ± 5.2 71.5 ± 9.1 -1.5 (-6.2, 3.1) 0.502 0.059 0.055 
PWV (m/s) 9.2 ± 1.2 9.0 ± 1.4 -0.2 (-0.6, 0.3) 0.716  8.9 ± 0.9 9.1 ± 1.5 0.2 (-0.5, 1.0) 0.430 0.504 0.409 
PWA (AI %) 28.7 ± 4.4 27.6 ± 5.7 -1.1 (-3.6, 1.3) 0.255  29.6 ± 3.9 30.7 ± 7.3 1.1 (-2.1, 4.3) 0.386 0.242 0.201 
            
Hypertensivef n 18    n 19     
SBP (mmHg) (Office) 137.5 ± 11.7 136.5 ± 11.6 -2.2 (-5.6, 1.2) 0.201  138.5 ± 9.9 135.3 ± 11.1 -1.0 (-4.2, 2.1) 0.508 0.829 0.828 
DBP (mmHg) (Office) 89.6 ± 7.2 89.8 ± 8.1 -0.3 (-2.0, 1.9) 0.971  90.9 ± 7.1 88.6 ± 8.4 -1.1 (-3.3, 1.1) 0.333 0.483 0.475 
SBP (mmHg) (Central) 138.1 ± 11.0 136.2 ± 10.1 -2.1 (-5.8, 1.6) 0.214  137.2 ± 8.8 135.6 ± 10.6 -1.0 (-4.6, 2.5) 0.468 0.781 0.895 
DBP (mmHg) (Central) 77.9 ± 5.5 77.0 ± 6.8 -0.9 (-3.0, 1.1) 0.460  77.3 ± 7.2 77.2 ± 7.4 -0.2 (-2.1, 1.7) 0.711 0.099 0.126 
PWV (m/s) 9.0 ± 1.6 9.2 ± 1.2 0.1 (-0.3, 0.6) 0.412  9.4 ± 1.3 9.4 ± 1.2 -0.1 (-0.5, 0.4) 0.864 0.613 0.471 
PWA (AI %) 27.3 ± 7.4 27.9 ± 8.4 0.5 (-1.5, 2.5) 0.504   25.5 ± 6.7 27.8 ± 8.9 2.2 (-0.1, 4.4) 0.092 0.328 0.241 
 
 
 
  
Mean ± SD (all such values). SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, pulse wave velocity; PWA, pulse wave analysis;  
AI, augmentation index 
a Mean change (Post-intervention – baseline) 
b P for Intra (within) -group comparison (Paired student’s t test) 
c P for Inter (between) -group comparison (Independent student’s t test) 
d P for Inter-group comparison (Univariate ANCOVA model adjusted for baseline value for the dependent variable, gender, age and waist circumference) 
e SBP ≤ 140mm Hg and/or DBP ≤ 90 mmHg (17) 
f SBP > 140mm Hg and/or DBP > 90 mmHg (17) 
 
22 
 
 
 
Figure 1  CONSORT Flow diagram of participants 
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Online Resources (Supplemental Information) 
 
Manuscript Title: Effect of an egg ovalbumin-derived protein hydrolysate on blood pressure and 
cardiovascular risk in adults with a mildly elevated blood pressure: a randomized placebo-controlled 
crossover trial 
 
 
Online Resource 1 The nutrient composition of study treatments (one sachet = 3g). 
Nutritional information per 3g 
sachet 
Ovalbumin-derived peptide 
digestate fraction 
Placebo 
(Maltodextrin) 
Energy (kJ) 47.5 52.7 
Protein (g) 2.8 <1.0 
Total carbohydrate (g) <1.0 3.0 
Fat (g) <1.0 <1 
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Online Resource 2 Flow diagram of study visits 
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For review purposes: Online Resource 3 reports intention-to –treat analysis 
Online Resource 3  Measures of blood pressure and cardiovascular risk stratified by treatment allocated 
 Ovalbumin egg-peptide (n 74) Placebo (n 74)      
  Baseline Endpoint 
Mean changea (95% 
CI) Pb Baseline Endpoint 
Mean changea (95% 
CI) Pb Pc Pd 
SBP (mmHg) (Office) 
132.8 
±12.8 
133.5 
±12.3 -0.6 (-3.4, 2.2) 0.654 
134.9 ± 
10.9 
132.4 ± 
11.9 -0.8 (-3.4, 1.8) 0.436 0.743 0.471 
DBP (mmHg) (Office) 88.1 ± 7.2 88.8 ± 8.2 0.3 (-1.3, 1.9) 0.708 88.0 ± 7.9 87.2 ± 8.1 -0.2 (-1.9, 1.4) 0.760 0.631 0.309 
SBP (mmHg) (Central) 
135.9 
±12.2 
135.7 
±11.3 -0.4 (-3.2, 2.5) 0.666 
134.3 ± 
10.7 
133.7 ± 
11.7 -0.1 (-2.8, 2.6) 0.690 0.556 0.660 
DBP (mmHg) (Central) 76.3 ± 6.5 76.1 ± 6.2 -0.6 (-2.1, 0.9) 0.929 75.7 ± 7.5 75.4 ± 8.6 -0.2 (-2.1, 1.7) 0.730 0.441 0.857 
PWV (m/s) 9.1 ± 1.5 9.2 ± 1.4 0.06 (-0.3, 0.4) 0.473 9.3 ± 1.2 9.2 ± 1.3 0.06 (-0.3, 0.4) 0.341 0.797 0.968 
PWA (AI %) 27.9 ± 6.9 27.6 ± 7.7 -0.2 (-1.8, 1.5) 0.909 26.9 ± 6.2 28.8 ± 8.4 1.6 (-0.2, 3.3) 0.083 0.159 0.093 
Total-Cholesterol 
(mmol/L) 5.68 ± 1.1 5.75 ± 1.1 0.03 (-0.2, 0.2) 0.790 5.67 ± 1.0 5.91 ± 1.1 0.2 (-0.01, 0.5) 0.048 0.146 0.147 
HDL-Cholesterol 
(mmol/L) 1.52 ± 0.6 1.56 ± 0.6 0.02 (-0.1, 0.1) 0.707 1.48 ± 0.7 1.64 ± 0.6 0.2 (0.1, 0.2) 0.001 0.077 0.076 
LDL-Cholesterol 
(mmol/L) 3.66 ± 0.9 3.61 ± 0.9 -0.1 (-0.3, 0.1) 0.413 3.65 ± 0.9 3.72 ± 0.9 0.1 (-0.1, 0.3) 0.495 0.281 0.288 
Triglycerides (mmol/L) 1.32 ± 1.3 1.22 ± 0.7 -0.1 (-0.3, 0.2) 0.513 1.36± 1.5 1.33 ± 1.2 -0.03 (-0.2, 0.1) 0.690 0.982 0.955 
Glucose (mmol/L) 5.62 ± 0.9 5.62 ± 0.8 0.04 (-0.2, 0.2) 0.638 5.68 ± 0.8 5.69 ± 0.9 -0.03 (-0.3, 0.2) 0.939 0.642 0.533 
 
 
 
 
Mean ± SD (all such values); BP, blood pressure; PWV, pulse wave velocity; PWA, pulse wave analysis; AI, augmentation index 
a Mean change (Post-intervention – baseline) 
b P for Intra (within) -group comparison (Paired student’s t test) 
c P for Inter (between) -group comparison (Independent student’s t test) 
d P for Inter-group comparison (GLM ANCOVA model adjusted for baseline value for the dependent variable, gender, age and waist circumference) 
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